Specify a stock or a cryptocurrency in the search bar to get a summary
Marker Therapeutics Inc
MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Address: 9350 Kirby Drive, Houston, TX, United States, 77054
Analytics
WallStreet Target Price
15.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MRKR
Dividend Analytics MRKR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MRKR
Stock Valuation MRKR
Financials MRKR
Results | 2019 | Dynamics |